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Abstract
Background
Sleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan para-
sites and characterized by a chronic progressive course, which may last up to several years
before death. We conducted two Phase 2 studies to determine the efficacy and safety of
oral pafuramidine in African patients with first stage HAT.
Methods
The Phase 2a study was an open-label, non-controlled, proof-of-concept study where 32
patients were treated with 100 mg of pafuramidine orally twice a day (BID) for 5 days at two
trypanosomiasis reference centers (Angola and the Democratic Republic of the Congo
[DRC]) between August 2001 and November 2004. The Phase 2b study compared
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pafuramidine in 41 patients versus standard pentamidine therapy in 40 patients. The Phase
2b study was open-label, parallel-group, controlled, randomized, and conducted at two
sites in the DRC between April 2003 and February 2007. The Phase 2b study was then
amended to add an open-label sequence (Phase 2b-2), where 30 patients received pafura-
midine for 10 days. The primary efficacy endpoint was parasitologic cure at 24 hours
(Phase 2a) or 3 months (Phase 2b) after treatment completion. The primary safety outcome
was the rate of occurrence of World Health Organization Toxicity Scale Grade 3 or higher
adverse events. All subjects provided written informed consent.
Findings/Conclusion
Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine
after 10 days of dosing. The cure rates 3 months post-treatment were 79% in the 5-day
pafuramidine, 100% in the 7-day pentamidine, and 93% in the 10-day pafuramidine groups.
In Phase 2b, the percentage of patients with at least 1 treatment-emergent adverse event
was notably higher after pentamidine treatment (93%) than pafuramidine treatment for 5
days (25%) and 10 days (57%). These results support continuation of the development pro-
gram for pafuramidine into Phase 3.
Author Summary
Sleeping sickness (human African trypanosomiasis [HAT]) is caused by parasites, and has
a chronic progressive course that may last from several months to several years before
death occurs. The present studies were done to assess the effectiveness and safety of oral
pafuramidine versus intramuscular pentamidine (the standard treatment), in patients with
first stage HAT. The results indicated that, several months after treatment, pafuramidine
administered for 10 days was as effective as pentamidine administered for 7 days, and it
had a better safety profile than pentamidine. With further study, pafuramidine could be a
promising alternative for patients with first stage HAT. In addition, the design of the stud-
ies can be used a guide for future studies for identification and delivery of treatment to
affected individuals in rural Africa.
Introduction
Sleeping sickness (human African trypanosomiasis [HAT]) is a neglected tropical disease with
limited treatment options that currently requires parenteral administration. It is caused by the
protozoan parasites Trypanosoma brucei (T.b.) gambiense (the West African form of the dis-
ease) and Trypanosoma brucei rhodesiense (the East African form of the disease). T.b. gam-
biense is found in 24 countries in west and central Africa and currently accounts for over 98%
of reported cases of sleeping sickness [1]. Sleeping sickness due to T.b. gambiense is character-
ized by a chronic progressive course, which may last from several months to several years
before death occurs. The disease has two defined stages. The first stage is characterized by try-
panosomes in the hemolymphatic system, which multiply in subcutaneous tissues, blood, and
lymph. First stage symptoms entail bouts of fever, headaches, joint pains and itching. In the
first stage, a person can be infected for months or even years without major signs or symptoms
of the disease. When more evident symptoms emerge, the patient is often already in an
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advanced disease stage where the central nervous system is affected (second stage). The second
(or neurological) stage begins once parasites penetrate the central nervous system, where their
presence initiates deterioration in neurological function, including disruption of sleep/wake
patterns that lend the name “sleeping sickness” to this stage of the disease [1].
After resurgence of the disease in the 1990s, the number of annual cases has subsequently
dropped to less than 10,000 in recent years [2, 3]. Although the global incidence of HAT seems
to be declining, several non-governmental organizations have cautioned that HAT still remains
a “hidden epidemic” in regions impacted by civil war, such as the northeastern Democratic
Republic of the Congo (DRC), southern Sudan, and the Central African Republic [4].
The socioeconomic burden on a household with an individual with HAT is high; between
1.5 and 10 months of household income can be lost, even when the diagnostics and antitrypa-
nosomal drugs are provided free of charge. The extraordinary burden that HAT places on
affected households and communities is often not very visible in national or regional health
data because of its focal nature, and the disease often falls very heavily on a few locations [4].
The majority of current HAT research is focused on the second stage of the disease, which
requires drugs that can cross the blood-brain barrier. The organo-arsenic compound melarso-
prol has until very recently been the most widely used drug for treatment of second stage HAT,
but because of its toxicity (encephalopathic syndrome, associated with 5–10% mortality), it is
being progressively replaced by nifurtimox-eflornithine combination therapy [5]. The nifurti-
mox-eflornithine combination was placed on the World Health Organization (WHO) list of
essential medicines and has been increasingly used [6, 7]. In addition, several new molecules
have also shown promise for the treatment of second stage HAT. The most developmentally
advanced of these compounds is fexinidazole, which has completed a Phase 1 clinical study
and is now in Phase II/III evaluation [8].Two diamidine analogues [9, 10] and a benzoxaborole
compound [11] have also exhibited promising activity (short in vitro time to kill and no cross-
resistance) in animal models of second stage HAT.
An effective, safe drug for stage 1 HAT that can be easily administered in rural African set-
tings is critically needed. There is no vaccine for T.b. gambienseHAT and only two drugs are
approved for treatment of stage 1 disease: pentamidine (in the field only used for T.b. gam-
biense) and suramin (only for only for T.b. rhodesiense). In expatriate patients, pentamidine is
currently the treatment of choice since is it generally well tolerated, whereas suramin can cause
undesirable effects in the urinary tract in addition to allergic reactions [1]. Pentamidine is
administered by the intramuscular route and has a reported treatment failure rate after a course
of five injections of approximately 7% [12, 13, 14]. Despite this encouraging efficacy profile,
treatment with pentamidine has limitations. It requires injection, which hampers its use in
rural treatment facilities. Though adverse reactions are usually reversible and persistent mani-
festation of its most serious long-term consequence, diabetes, is rare, a high frequency of
adverse events, including hypotension, nephrotoxic effects, leukopenia, and hypo- and hyper-
glycemia, has been noted [15, 16].
Pafuramidine (DB289) is the orally available dimethoxime prodrug of DB75 (furamidine), a
novel diphenylfuran diamidine shown to be active in vitro against African trypanosomes and
in animal models for trypanosomiasis [17, 18]. Pafuramidine is potentially a significant
improvement over pentamidine, the drug currently used to treat first stage HAT. Its oral for-
mulation greatly facilitates administration under challenging field conditions and makes pafur-
amidine readily available not only in sleeping sickness centers, but also public health facilities.
Further, high doses of pafuramidine have been remarkably well tolerated in animal models of
trypanosomiasis [19] and Pneumocystis jiroveci (a fungal infection of the lungs, formerly called
Pneumocystis carinii, or PCP pneumonia) [20]. In addition, the prodrug pafuramidine and its
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active metabolite (DB75) have shown increased efficacy compared to pentamidine in animal
models of T.b. rhodesiense infection [17, 19].
Prior to the initiation of the current Phase 2a study, pafuramidine had been successfully
administered to healthy volunteers in both single-dose and multiple-dose studies, to evaluate
the safety of pafuramidine and the pharmacokinetics (PK) of pafuramidine and DB75 [21].
Overall, multiple-dose treatment was well tolerated up to the maximum dose of 100 mg twice a
day (BID), and was also well tolerated in the single-dose study up to 600 mg, although there
was no substantially increased area under the plasma drug concentration versus time curve at
doses above 100 mg.
The objectives of the present Phase 2 studies were to assess, for the first time, the efficacy,
safety, and dosage of pafuramidine (Phase 2a), and to compare the efficacy, safety, and dosage
of oral pafuramidine versus intramuscular pentamidine (Phases 2b and 2b-2) for treatment of
first stage T.b. gambiense sleeping sickness. Pafuramidine may offer a potentially significant
improvement over pentamidine, since it is orally administered and may be better tolerated.
Methods
Ethics Statement
All subjects provided written informed consent. This will certify that the Institutional Review
Boards (IRBs) at the University of North Carolina at Chapel Hill, administered by the Office of
Human Research Ethics, are organized and operate according to applicable laws and regula-
tions governing research involving human subjects. These include, when applicable, statutes of
the State of North Carolina and regulations of the Food and Drug Administration (21 CFR 50
and 56) and the Department of Health and Human Services [45 CFR 46 (the "Common Rule")
and 45 CFR 164 (the Health Insurance Portability and Accountability Act, HIPPAA]. In addi-
tion, the IRBs conform, when applicable, to Good Clinical Practice (GCP) guidelines of the
International Conference of Harmonization (ICH), to the extent these do not contradict
DHHS and FDA regulations. The University of North Carolina at Chapel Hill holds a Federal-
wide Assurance, FWA 4801, approved by the federal Office for Human Research Protections
(OHRP). These studies were approved by the following independent ethics committees: Ethik-
kommission beider Basel, EKBB, Comité de Ética Republica de Angola, and Comité Éthique
République Démocratique du Congo. IRB# 01-PATH/LAB-308. International Protocol
#289-C-006.
Design
The Phase 2a study was a multi-center, multi-country, open-label, non-controlled, proof-of-
concept study to assess the efficacy and safety of pafuramidine in 32 patients with first stage T.
b. gambiense sleeping sickness. Patients were treated with 100 mg of pafuramidine orally BID
for 5 days, and were hospitalized for a total of 12 days including a 6-day post-dose observation
period. This study was conducted at two trypanosomiasis reference centers: one in Viana,
Angola, and one in Maluku, Democratic Republic of the Congo (DRC) from 31 August 2001
(first patient enrolled) to 28 November 2004 (last patient follow-up completed). This study was
approved by the following independent ethics committees: Ethikkommission beider Basel,
EKBB, Comité de Ética Republica de Angola, and Comité Éthique République Démocratique
du Congo.
The Phase 2b study was an open-label, parallel group, controlled, randomized trial to com-
pare the efficacy and safety of pafuramidine with standard pentamidine treatment in 81
patients with first stage T.b. gambiense sleeping sickness. Patients were randomized (1:1) to
either pafuramidine 100 mg BID administered orally for 5 days (n = 41) or pentamidine
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intramuscular injections (4 mg/kg QD) for 7 days (n = 40). This study was conducted at two
sites: one trypanosomiasis reference center (Maluku, DRC) and one hospital (Vanga, DRC)
from 01 April 2003 (first patient enrolled) to 08 February 2007 (last patient follow-up com-
pleted). This study also included a substudy/subset of patients enrolled at selected sites to assess
the incidence and severity of laboratory anomalies (including aspartate aminotransferase
[AST]/alanine aminotransferase [ALT] and glycemia) and incidence of electrocardiogram
(ECG) anomalies.
The Phase 2b protocol was later amended to add an open-label study sequence (Phase 2b-
2), in which an additional 30 patients were recruited at the same sites to confirm safety and effi-
cacy of prolonged pafuramidine treatment. These patients received 100 mg of pafuramidine
BID for 10 days with a total hospitalization time of 14 days.
The Phase 2b and 2b-2 studies were approved by the Ethikkommission beider Basel, EKBB,
Committee on the Protection of the Rights of Human Patients, University of North Carolina
Chapel Hill, and Comité Ethique Republique Democratique du Congo.
In all studies, patients were stratified by site to ensure similar numbers of enrolled patients
at each site. The flowchart for all the Phase 2 studies is depicted in Fig 1.
Changes to Trial Design
All study amendments were approved by the ethical committees and IRBs previously noted.
The Phase 2a amendment 1 included: 1) changed inclusion criterion for white blood cell
(WBC) count from 20 to 5 cells/mm-3 to reduce the possibility of enrolling undetected late
stage patients; 2) added a minimal weight of 40 kg to maintain consistency with Phase 1 trials;
3) added exclusion due to traumatic lumbar puncture to reduce the chance of incorrect staging
of the disease at diagnosis; and 4) changed and refined the definition of treatment failures,
based on the improved diagnostic tools to be used in the trial.
Phase 2b amendment 1 added stricter rules for opening non-hospital-based sites for enrol-
ment, by adding a “delay” of treating 40 patients. Phase 2b recruitment was subsequently ter-
minated before opening accrual to rural sites and protocol modifications were implemented
after five treatment failures were observed directly after treatment in the 5-day pafuramidine
group in Phase 2a. After examination of the PK properties of pafuramidine, in particular, the
lack of proportional conversion of DB289 to DB75 at therapeutic doses [22, 23], we decided
against using a higher dose to improve efficacy for the modified protocol and instead increased
pafuramidine treatment to 10 days at the same dose (100 mg BID) (Phase 2b-2) (Fig 2). Phase
2b amendment 3 added additional testing for parasites in lymph and circulating blood to
reduce the potential for false-negative tests provides a chronological representation of the con-
duct of each study and illustrates the time points at which decisions were made, based on pre-
liminary data, to proceed to the next study in the development program.
Study Patients
Male and female subjects were eligible to participate if they had first stage T.b. gambiense sleep-
ing sickness, documented by the presence of parasites in the blood or lymph and their absence
in the cerebrospinal fluid (CSF), confirmed by<5 mm-3 WBCs detected in the CSF by micro-
scopic examination. In the Phase 2a study, patients were 16 years or older, with a minimal
weight of 45 kg, and in the Phase 2b study, patients were 15 to 50 years of age with a minimal
weight of 35 kg. Women of childbearing potential were included if they were neither lactating
nor pregnant, and were instructed to abstain from sexual intercourse from the day of consent
until the end of the in-hospital observation period.
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Key criteria for exclusion for all patients included 1) late stage T.b. gambiense infection; 2)
active clinically relevant medical conditions that in the investigator’s opinion may have jeopar-
dized patient safety or interfere with participation in the study (eg, significant liver diseases,
chronic pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases,
gout, infection including acquired immune deficiency syndrome, central nervous system
trauma or seizure disorders); 3) traumatic lumbar puncture (red blood cells visible in CSF); 4)
clinically significant abnormal laboratory values at screening; 5) score of less than 9 on the
Glasgow Coma Scale; and 6) previous treatment for HAT.
Interventions
Patients in all studies provided written informed consent. Patients in the Phase 2a study were
screened either by mobile diagnostic teams or in the treatment centers. Patients with positive
results at the mobile units were referred to the study sites for repeat testing. Patients in the
Phase 2b and Phase 2b-2 studies were screened only in the treatment centers. Screening for T.
b. gambiense was done using the card agglutination test for trypanosomes [24, 25]. All patients
Fig 1. CONSORT flowchart for pafuramidine phase 2 studies.
doi:10.1371/journal.pntd.0004362.g001
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were tested for malaria and filaria in thick blood smears and, if indicated, malaria treatment
was given before study enrolment; filariasis therapy was administered after study treatment.
All patients who had palpable lymph nodes underwent puncture at the screening or baseline
visit. The aspirate was assessed microscopically for trypanosomes and if the result was negative,
a blood sample was examined by hematocrit centrifugation and miniature anion exchange cen-
trifugation technique. Lumbar puncture was performed in all positive cases detected by either
method and the disease stage was determined by microscopic examination of CSF for trypano-
somes and by WBC counts. Other screening and baseline evaluations included demographic
and medical history, concomitant medications, vital signs, and physical examination including
the Coma Scale. In all studies, baseline ECGs were performed and evaluated by a cardiologist
to confirm patient inclusion.
Clinical supplies of pafuramidine were provided to the sites in bottles (50 gel caps of 100
mg) labelled to indicate study drug, strength, expiration date, protocol number, and other
information according to local regulations. Pentamidine was provided locally as pentamidine
isethionate for injection in single-dose vials at 200 mg per vial. Study drugs were stored at
ambient temperature.
During the treatment periods in all studies, routine safety assessments included examina-
tions for possible treatment-emergent adverse events, physical examinations, hematology tests
(hemoglobin and leukocyte count), and chemistry profile (serum glucose, creatinine, AST,
ALT, total bilirubin, urea, and C reactive protein).
Fig 2. Schematic representation of the clinical development program.
doi:10.1371/journal.pntd.0004362.g002
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In the Phase 2a study, patients were administered 100 mg of pafuramidine orally BID
(morning and evening) for 5 days. In addition to the safety assessments previously mentioned,
prothrombin time was also evaluated. For PK analyses, blood plasma levels were collected just
before dosing and at several time points after the last dose. The 6-day post-dose observation
period included additional ECGs after the last dose of study drug on Day 6; lymph node punc-
ture and lumbar puncture on Day 7 (24 hours after last treatment, which is the primary end-
point); plasma samples for PK analyses; and a CSF sample for PK analysis on Day 7. Follow-up
visits to evaluate treatment outcomes continued for 24 months, with lymph node punctures at
Months 3, 6, 12, and 24 and lumbar punctures at Months 12 and 24.
In the Phase 2b study, patients received either pafuramidine 100 mg administered orally
BID for 5 days or pentamidine intramuscular injections (4 mg/kg, once a day [QD]) for 7 days.
Patients in both treatment groups stayed in the hospital for 7 days. In addition to the previously
mentioned routine safety assessments, female patients in this study underwent pregnancy tests
at baseline and end of treatment. A lymph node and lumbar puncture were also done at Day 7
(end of treatment). For patients in the substudy, blood samples for PK analyses were taken
after the last dose on Day 6 and 7; ECGs were repeated on Days 1, 3, 7, and 9; and hematology
and chemistry tests were repeated at Day 9. Follow-up visits to evaluate treatment outcomes
continued for a period of 24 months, with lymph node, lumbar punctures, and a CSF sample at
Month 3, 6, 12, and 24.
As part of Phase 2 amendment 2, patients received 100 mg of pafuramidine BID for 10 days
with a total hospitalization time of 14 days. Study procedures in Phase 2b-2 were identical to
Phase 2b, except the post-treatment procedures were done at Days 12 and 14. Follow-up visits
to evaluate treatment outcomes also continued for a period of 24 months, with lymph node
and lumbar punctures and a CSF sample as noted above.
Outcomes. The primary efficacy endpoint was the parasitological cure rate 24 hours after
completion of treatment in Phase 2a (Day 7), and 3 months after completion of treatment in
both Phase 2b studies. The primary determinants of parasitological cure were the absence of
parasites in blood, lymph nodes, and CSF, as well as<5 mm-3 WBCs in the CSF 24 hours
(Phase 2a) or 3 months (Phase 2b) after the last dose of pafuramidine. Parasitological cure/
treatment failure was assessed after treatment by searching for the presence of parasites in
blood and lymph by hematocrit centrifugation [26] and miniature anion exchange centrifuga-
tion technique [27].
A “relapse” was any recurrence of trypanosomes or surrogate signs during the follow-up
period. Relapses included both confirmed and suspected relapses. For a confirmed relapse, try-
panosomes were observed in blood, lymph, or CSF at any follow-up examination. For a sus-
pected relapse, the WBC count increased to more than 50 cells mm-3 or the WBC count was 6
to 49 cells mm-3 and the patient had clear symptoms attributed to relapse (somnolence, long-
lasting headache, and recurrent fever).
A “treatment failure” was a non-response to the study drug at the end of treatment. For a
confirmed treatment failure, trypanosomes were found in blood, lymph, or CSF at post-treat-
ment or any follow-up examination. A suspected treatment failure was reported if there was
either 1) at least a fourfold increase in the serum titers of at least two of the applied tests com-
pared to the post-treatment values or the preceding follow-up values, followed by a test repeti-
tion 1 month thereafter or 2) at least a fourfold increase in the CSF titers in the two applied
tests compared to the post-treatment values or the preceding follow-up values, or an increase
of WBC in the CSF above 20 mm3 followed by a test repetition 1 month thereafter in the
absence of another likely diagnosis. Patients with treatment failures were treated (according to
the national guidelines) with either pentamidine or melarsoprol. There was no discrimination
between treatment failures and reinfections.
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The primary outcome measure for the safety analysis in all studies was the rate of occur-
rence of WHO Grade 3 or higher treatment-emergent adverse events. The term “adverse
event” could include any of the following events that developed or increased in severity during
the course of the study: 1) any signs or symptoms whether thought to be related or unrelated to
the condition under study; 2) any clinically significant laboratory abnormality; or 3) any abnor-
mality detected during physical examination. Adverse events were graded by the investigator
according to the WHO Toxicity Scale (1 = mild, 2 = moderate, 3 = severe, 4 = potentially life
threatening). Adverse events were assessed at every study visit and were classified according to
the terms found in the Medical Dictionary for Regulatory Activities (MedDRA).
A serious adverse event was defined as any event that suggested a significant hazard, contra-
indication, side effect, or precaution. A serious adverse event included any event that: 1) is
fatal; 2) is life threatening; 3) is a persistent or significant disability/incapacity; 4) requires or
prolongs in-patient hospitalization; 5) is a congenital anomaly/birth defect; or 6) is an impor-
tant medical event, based upon appropriate medical judgment that may jeopardize the patient
or may require medical or surgical intervention to prevent one of the other outcomes defined
as serious.
Changes to outcomes. In the Phase 2 trial, every resurgence of parasite during the follow
up and independent of the timing was considered as treatment failure. Based on consultation
with the WHO for an upcoming Phase 3 trial, treatment failures (parasites detected at the
24-hour lumbar puncture performed after treatment) were distinguished from relapses (re-
emergence of parasites at any time later during follow up). In the overall analysis both, treat-
ment failures and relapses were considered failures.
Sample Size
For the Phase 2a study, the sample size of 30 evaluable patients was considered to be sufficient
to meet the primary objective because this size was comparable to a typical Phase 1 pilot study.
Based on a non-inferiority approach, calculation of the Phase 2b sample size assumed a 2%
relapse rate in the pentamidine control group and a maximally accepted relapse rate of 10% in
the pafuramidine treatment group. To achieve a power of 90% to refute the null hypothesis, in
the event that the relapse rate of the new drug was equal to that of the standard (also 2%), 147
evaluable patients in each group were planned with a target enrolment of 175 patients in each
group. A dropout rate of 15% was expected by the first follow-up examination at 3 months
post-treatment.
The decision to continue the study in Phase 2b-2 with 30 evaluable patients was made based
on assumption of a set rate of treatment failures (parasite-positive analyses 24 hours after treat-
ment) and a binomial distribution for the number of relapses, and calculation of the probability
to have N or more relapses. It was appropriate to make the nominal significance level smaller
than 0.05 in order to keep the overall Type 1 error rate (the probability to incorrectly discard
the treatment tested as not effective) at 0.05 [28]. For example, with a sample size of 30 and an
assumed relapse rate of 1%, occurrence of 2 or more relapses had a 4% probability.
Stopping Guidelines and Interim Analysis
No interim analysis was planned or conducted. There was no formal stopping rule for the
Phase 2a and 2b trials. In case of accumulation of unexpected severe adverse events, the study
director and the sponsor's medical director could have decided, after consultation with the
advisory board chairperson, the investigator, and the country coordinator of the national HAT
programs of Angola (ICCT), whether the trial needed to be stopped. In case of a major protocol
violation by the investigator, the sponsor could have stopped the trial.
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For Phase 2b-2, the decision to continue the trial was based on accepting (or assuming) a set
rate of refractory cases (ie, a patient was parasite positive 24 hours after treatment) and a bino-
mial distribution for the number of relapses. The probability to have N or more refractory
cases in 30 patients can be seen in Table 1.
Randomization
In all studies, patients were assigned a patient number in the order in which they enrolled,
starting with Patient -001. In Phase 2a, there was no randomization since the study was open
label. In Phase 2b, patients were randomized (1:1) in blocks of 10 in the order in which they
were enrolled, stratified by clinical site, according to a randomization schedule prepared at
Immtech International. Each study site was provided with series of individual envelopes each
containing a card with the treatment assignment for 1 patient and a control number. After a
patient signed the informed consent and inclusion/exclusion criteria were confirmed, the
investigator opened the next envelope in the randomization list to obtain treatment assignment
for that patient, then transferred the control number to the patient’s case report form.
Patients were identified on the case report forms by the patient number, initials, study cen-
ter, and study identification numbers. The investigators kept a separate confidential enrolment
log that matched identifying codes with the patients’ names and residences. The process was
carefully monitored during the trial and envelopes were designed in a way that did not allow
tampering or identification of the documentation inside.
Blinding
There was no blinding in the studies due to the different routes of administration. Phase 2a and
Phase 2b-2 were non-controlled studies.
Statistical Methods
For the Phase 2a study, the parasitological cure rate was calculated as 100 minus the combined
relapse and treatment failure rates at the specified time point. The denominator for computa-
tion of relapse rates was the number completing treatment.
The evaluable population used in the efficacy assessments reported for Phase 2b included
patients who completed treatment with the assigned regimen of study medication and who
either had a treatment failure or a relapse at any time prior to the scheduled time point of inter-
est or underwent diagnostic procedures at the time point of interest or later. The last observa-
tion carried backwards was used for patients with missing data who had an assessment at a
later visit, as long as the patient was not a relapse. For example, if a patient’s last visit was prior
to 3 months (ie, the patient was lost to follow-up after the end-of-treatment visit), the patient
was considered to be a relapse at 3 months.
For the Phase 2b and 2b-2 studies, the number and percentage of patients with parasitologi-
cal cure at each evaluation was summarized by treatment group (pafuramidine for 5 days,
pafuramidine for 10 days, and pentamidine for 7 days). The denominator included patients
who had parasitologically confirmed infection with T.b. gambiense prior to treatment, com-
pleted the assigned regimen of study medication, and underwent diagnostic procedures at the
end of treatment visit. All efficacy data were tabulated.
All patients who received treatment with the study drug were included in the analysis of
safety and tolerability. In all cases, the primary outcome measure for safety analysis was the
rate of occurrence of WHO Toxicity Scale Grade 3 (severe) or Grade 4 (potentially life-threat-
ening) adverse events during the observation period. All safety data, including vital signs and
adverse events, were tabulated.
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All statistical analyses were performed with commercially available software (SAS version
9.0).
Results
Participant Flow
The Phase 2a study recruited patients from 31 August 2001 (first patient enrolled) to 28
November 2004 (last patient follow-up completed) and the Phase 2b study recruited patients
from 01 April 2003 (first patient enrolled) to 08 February 2007 (last patient follow-up
completed).
First stage HAT patients rarely present at a hospital or a treatment center. Therefore, intense
screening activities were necessary to identify first stage patients. A total of 107,354 patients
were screened to find 869 patients affected with HAT: 360 in Phase 2a, 311 in Phase 2b, and 198
in Phase 2b-2 (Fig 1). The exclusion rate was high (726 of 869 patients, 83.5%); primary reasons
were stage 2 HAT, unknown disease stage, and inclusion criteria not met. Despite the high rate
of screening exclusion, 32 patients were randomized and treated in Phase 2a, 81 patients in
Phase 2b (40 to pafuramidine and 41 to pentamidine), and 30 patients in Phase 2b-2.
As shown in Table 2, study completion rates were high: 29 of 32 (90.6%) patients in Phase
2a, and 100% in both Phase 2b studies. In Phase 2a, 2 patients discontinued due to adverse
events and 1 patient discontinued for administrative reasons. The follow-up attendance at
Month 24 in all Phase 2b treatment groups was very good through the last assessment. A total
of 83% (33 of 40) of patients treated with pafuramidine for 5 days, 78% (32 of 41) of patients
treated with pentamidine, and 70% (21 of 30) patients treated with pafuramidine for 10 days
underwent evaluation at the 24-month follow-up visit.
Baseline Data
Demographic variables (age, gender, weight, height, and body mass index) were summarized
for all study patients (Table 3). Across studies, the treatment groups were similar with respect
to age, distribution of men and women, height, weight, and body mass index.
Within the Phase 2b study, the treatment groups were also comparable in the time elapsed
since symptoms were first observed, and the majority of patients in each treatment group were
negative for malaria (range: 87% to 88%) and filaria (range: 83% to 100%), and did not have
diarrhea at hospital entry (range: 98% to 100%).
Numbers Analysed and Excluded
As shown in Fig 1, 29 of 32 patients (90.6%) in Phase 2a, 39 of 40 patients (97.5%) in the Phase
2b pafuramidine 5-day group, all 40 patients in the pentamidine group, and 28 of 30 (93.3%) of
patients in the pafuramidine 10-day group were included in the efficacy analysis. There were only
7 patients excluded from the efficacy analysis: 3 in Phase 2a (due to premature discontinuation),
Table 1. The probability of refractory cases.
Total Number of Patients
Treated
Set Rate of Refractory Cases
Accepted
Observed Refractory
Case (N)
Observed Rate of
Refractory Cases
Probability of N or more
cases
Sequence 2
30 2% 3 10.0% 0.02
30 2% 2 6.6% 0.12
30 1% 1 3.3% 0.04
doi:10.1371/journal.pntd.0004362.t001
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2 in Phase 2b (1 patient in each group lost to follow-up), and 2 patients in Phase 2b-2 (lost to fol-
low-up). There were no protocol deviations.
Outcomes and estimations. As shown in Table 4, the parasitological cure rate 24 hours
after the last treatment (primary endpoint) in the Phase 2a study was 93% (27 of 29 patients).
All of the patients were negative for parasites in blood and CSF, while 2 patients remained posi-
tive for parasites in lymph nodes. The 93% cure rate (26 of 28 patients) was maintained at
Month 3 and then declined to 67% (14 of 21 patients) at 24 months post-treatment. Five
patients were considered relapses during the post-treatment follow-up period. This high num-
ber of relapses during the follow-up period of the Phase 2a study led to the termination of
Phase 2b recruitment and revision of the protocol to a 10-day treatment period.
The Phase 2b cure rates at the primary endpoint (3 months after treatment) were comparable
across treatment groups: 79% (31 of 39 patients) in the pafuramidine 5-day treatment group,
100% (40 of 40 patients) in the pentamidine 7-day group, and 93% in the 10-day pafuramidine
extended treatment group (Table 4). Five treatment failures, all with persistent trypanosomes in
the lymph nodes, were observed directly after treatment in the 5-day pafuramidine group
The rate of patients with parasitological cure during the follow-up period at 6, 12, and 24
months was slightly higher in the pentamidine group (97%, 94%, and 97%, respectively) com-
pared to the pafuramidine 5-day group (82%, 83%, and 82%, respectively), but was comparable
to the pafuramidine 10-day group (84%, 84%, and 90%, respectively) (Table 4). No treatment
failures were observed directly after treatment in the pafuramidine 10-day group.
Harms
All enrolled patients were included in the safety analysis. As shown in Table 5, in the Phase 2a
study, the majority of adverse events were mild (Grade 1) or moderate (Grade 2) and the most
Table 2. Patient dispositions.
Phase 2a Pafuramidine 100 mg
BID (5 days) N = 32
Phase 2b N = 81 Phase 2b-2 Pafuramidine 100
mg BID (10 days) N = 30
Pafuramidine 100 mg BID
(5 days) N = 40
Pentamidine 4 mg/kg QD
(7 days) N = 41
Randomized 32 40 41 30
Treated 32 40 41 30
Completed
treatment
29 40 41 30
Discontinued
treatment
3 0 0 0
Withdrawn
Adverse event 2
Withdrawn
Administrative 1
Evaluable time
points
24 hours 29 (100%) ND ND ND
3 months 28 (96%) 39 (98%) 40 (98%) 28 (93%)
6 months 27 (93%) 38 (95%) 39 (95%) 25 (83%)
12 months 24 (83%) 36 (90%) 36 (88%) 25 (83%)
24 months 21 (72%) 33 (83%) 32 (78%) 21 (70%)
BID = twice a day; QD = once daily; ND = not determined
doi:10.1371/journal.pntd.0004362.t002
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commonly reported adverse events were headache (44%, 14 of 32 patients) and pyrexia (9%, 3
of 32 patients). There was only 1 patient with a severe (Grade 3) adverse event in the Phase 2a
study (hypertension, unspecified, lasting for 1 day), which led to premature discontinuation of
the study drug. One additional patient prematurely discontinued the study drug to an adverse
event of moderate (Grade 2) pyrexia (the duration of the event is not available). There were no
events higher than Grade 3.
No adverse event was considered possibly or probably related to the study drug and no seri-
ous adverse events were reported. There were minor increases in mean ALT, AST, and creati-
nine values, but these changes were not considered to be clinically significant; no patient
experienced a2-fold increase in ALT or AST.
As shown in Table 6, the overall rate of patients with treatment-emergent adverse events in
the Phase 2b studies was higher among patients who received pentamidine (93%, 38 of 41
patients) than in patients who received pafuramidine for 5 days (25%, 10 of 40 patients) or 10
days (57%, 17 of 30 patients). The most commonly reported adverse events were ALT
Table 3. Baseline demographics.
Phase 2a Pafuramidine 100mg
BID 5 days (N = 32)
Phase 2b Pafuramidine 100
mg BID5 days (N = 40)
Phase 2b Pentamidine 4 mg/
kg QD 7 days (N = 41)
Phase 2b-2 Pafuramidine 100
mg BID 10 days (N = 30)
Age
(years)
Mean
(SD)
36.2 (11.03) 31.8 (10.47) 30.6 (10.73) 33.1 (11.99)
Median 38 32 31 32
Min,
max
18, 63 15, 48 15, 50 15, 50
Sex, n
(%)
Female 18 (56) 25 (63) 22 (54) 21 (70)
Male 14 (44) 15 (37) 19 (46) 9 (30)
Height
(cm)
Mean
(SD)
167.7 (7.73) 160.9 (7.32) 161.6 (8.30) 160.4 (8.27)
Median 168 160 160 160
Min,
max
154, 182 150, 185 145, 177 142, 178
Weight
(kg)
Mean
(SD)
56.5 (7.01) 48.7 (8.04) 48.5 (7.59) 47.8 (6.55)
Median 55 47 48 48
Min,
max
46, 68 37, 69 34, 62 35, 59
BMI (kg/
cm2)
Mean
(SD)
20.0 (1.35) 18.7 (2.50) 18.6 (2.60) 18.6 (2.12)
Median 20 18.1 18.3 18.6
Min,
max
17, 22 14.7, 28.1 14.0, 26.0 14.9, 22.6
SD = standard deviation; BID = twice a day; QD = once daily; BMI = body mass index
doi:10.1371/journal.pntd.0004362.t003
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increased and AST increased, which were notably more prevalent in the pentamidine group
than in either of the pafuramidine groups. Specifically, in the pentamidine group, 71% (29 of
41) of patients experienced increased ALT; of these, 16 had severe (Grade 3) elevations. In
addition, a total of 85% (35 of 41) of pentamidine patients experienced increased AST. In the
pafuramidine 5-day and 10-day groups, increased ALT occurred in 1 and 3 patients, respec-
tively, and increased AST occurred in 4 and 5 patients, respectively. Elevations of liver enzymes
in HAT patients were concurrent with treatment, were considered mild, resolved spontane-
ously (within 2–4 days), and were asymptomatic.
Table 4. Parasitological cure rates (primary and secondary efficacy endpoints).
Phase 2a Pafuramidine 100 mg
BID 5 days N = 32
Phase 2b Phase 2b-2 Pafuramidine 100 mg
BID 10 days N = 30
Pafuramidine 100 mg BID 5
days N = 40
Pentamidine 4 mg/kg QD 7
days N = 41
24 hours 93% (27/29)a ND ND ND
3
months
93% (26/28) 79% (31/39)a 100% (40/40)a 93% (26/28)a
6
months
85% (23/27) 82% (31/38) 97% (38/39) 84% (21/25)
12
months
79% (19/24) 83% (30/36) 94% (34/36) 84% (21/25)
24
months
67% (14/21) 82% (27/33) 97% (31/32) 90% (19/21)
BID = twice a day; QD = once daily; ND = not determined
a Primary efficacy endpoint
doi:10.1371/journal.pntd.0004362.t004
Table 5. Treatment-emergent adverse events experienced by pafuramidin treated patients in the
Phase 2a study.
MedDRA System, Organ, Class Pafuramidine 100 mg BID 5 days (N = 32) n
(%)
Preferred Term
Severe (Grade 3)
Vascular disorders
Hypertension, unspecified 1 (3)
Mild to moderate (Grade 1 or Grade 2)
Nervous system disorders
Headache 14 (44)
General disorders and administration site
conditions
Pyrexia 3 (9)
Gastrointestinal disorders
Abdominal pain upper 1 (3)
Psychiatric disorders
Psychotic disorder, unspecified 1 (3)
Skin and subcutaneous tissue disorders
Pruritus 1 (3)
BID = twice daily; MedDRA = Medical Dictionary for Regulatory Activities
doi:10.1371/journal.pntd.0004362.t005
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Other severe (Grade 3) adverse events included hypertension (1 patient in the pentamidine
group) and headache (2 patients who received pentamidine and 1 patient who received pafura-
midine for 5 days). All events of headache were considered to be related to trypanosomiasis
and its treatment. No other Grade 3 or higher treatment-emergent adverse events were
reported.
There were 2 serious adverse events in the Phase 2b studies. One patient who received
pafuramidine for 5 days died 85 days after the last dose of the study drug. He was considered to
have probable second stage disease with rapid progression, and death due to encephalopathic
syndrome occurred during melarsoprol (rescue) treatment. One patient who received pentami-
dine was lost to follow-up after the 3-month evaluation and was subsequently reported to have
died of causes not likely to be related to trypanosomiasis.
Overall, pafuramidine was well tolerated in all Phase 2 studies, and the rate of treatment-
emergent adverse events was similar between the 5- and 10-day treatment groups. In the Phase
2b study, elevated ALT and AST values were more frequent in patients who received pentami-
dine 4 mg/kg QD for 7 days (71% and 85%, respectively) than in patients who received either
pafuramidine 100 mg BID for 5 days (3% and 10%, respectively) or 10 days (10% and 17%,
respectively).
Despite protocol-directed contraceptive measures, 2 pregnancies occurred during the treat-
ment period, (1 in Phase 2a and 1 in Phase 2b-2). The courses of the pregnancies were normal
and there were no abnormalities reported at birth. These children were repeatedly checked in
the treatment center until the end of the study and reported to be in overall good health with
normal development.
The ECGs from patients enrolled in these studies are included in a separately published
study on cardiac alterations in HAT [29]. The results of the analyses suggested that a prolonged
QTc interval, repolarization changes, and low voltage were significantly more frequent in first
and second stage HAT patients compared with healthy individuals, which did not change dur-
ing treatment with pafuramidine or pentamidine.
Table 6. Treatment-emergent adverse events experienced by3 patients in any treatment group in the Phase 2b studies.
MedDR Phase 2b Phase 2b-2
A System Organ Class Preferred
Term
Pafuramidine 100 mg BID 5
Days (N = 40) n (%)
Pentamidine 4 mg/kg QD 7
Days (N = 41) n (%)
Pafuramidine 100 mg BID 10
Days (N = 30) n (%)
Total patients with at least 1 adverse
event
10 (25) 38 (93) 17 (57)
General Disorders and Administration
Site Conditions
Asthenia 1 (3) 1 (2) 5 (17)
Injection site pain 0 9 (22) 0
Injection site reaction 0 4 (10) 0
Investigations
Alanine aminotransferase increased 1 (3) 29 (71) 3 (10)
Aspartate aminotransferase increased 4 (10) 35 (85) 5 (17)
Metabolism and Nutrition Disorders
Anorexia 0 1 (2) 3 (10)
doi:10.1371/journal.pntd.0004362.t006
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Discussion
Limitations
These were the first clinical studies in the field of trypanosomiasis conducted in the centers in
Angola and the DRC with local teams that were previously inexperienced in clinical studies.
However, they were fully compliant with Good Clinical Practice and regulatory standards.
Interpretation
The results reported here demonstrate the efficacy of 5-day pafuramidine for treatment of T.b
gambienseHAT with a 93% cure rate 24 hours post-treatment. Moreover, the parasitological
cure rate 3 months after treatment was comparable in the pentamidine 7-day group (100%)
and the 10-day pafuramidine treatment group (93%). The cure rate at 6, 12, and 24 months
remained comparable between the pentamidine 7-day group (97%, 94%, and 97%, respectively)
and the pafuramidine 10-day group (84%, 84%, and 90%, respectively). No treatment failures
were observed directly after treatment in the pafuramidine 10-day group.
Pafuramidine was well-tolerated in a treatment regimen of 100 mg given orally BID for 10
days, and the toxicity appeared to be less than that observed for pentamidine 4 mg/kg QD
given intramuscularly for 7 days. The efficacy (comparable to pentamidine) and safety (better
tolerated than pentamidine) results obtained with the extended 10-day dosing regimen of
pafuramidine support the continued clinical development of this drug.
Generalizability
From the perspective of study design, it is noteworthy that the 3-month surrogate endpoint for
efficacy used in the Phase 2b study effectively predicted the clinical outcomes determined at
the 24-month evaluation. Given that this 3-month endpoint was implemented based on the
progression of clinical efficacy observed in the Phase 2a study (with a primary endpoint at 24
hours post-treatment), the overall results represent one form of adaptive design for a series of
studies within a clinical development program.
The conduct of the studies also established an organization and infrastructure that greatly
facilitated the implementation of the subsequent Phase 3 study, eg, capacity building, improve-
ment of laboratory infrastructure, investment in and deployment of high quality laboratory
equipment, introduction of improved diagnostic methods, and improved experience in Inde-
pendent Ethics Committee set-up and support.
As noted, the conduct of these studies required large-scale screening, which was supported
by national HAT programs of Angola (ICCT) and DRC (PNLTHA). The success of the screen-
ing, in addition to the robust number of individuals who underwent screening, should contrib-
ute to improvement of HAT control in Angola and the DRC. The completion of the Phase 2
studies not only established the parameters for the design of a subsequent Phase 3 study, but
also provided a model for future studies of HAT in these and similar populations, and a blue-
print for the identification and delivery of treatment to affected individuals in rural Africa.
Registration
Both clinical trials were registered in the International Clinical Trials Registry Platform at
www.clinicaltrials.gov (Phase 2a study, NCT00802594; Phase 2b and 2b-2, NCT00803933).
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